Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-NM-02 for HER2 Detection in Breast Cancer
NCT04040686Phase 1Completed
- Sponsor
- Shanghai General Hospital
- Start
- Jul 2019
- Primary completion
- Dec 2021
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 99mTc-NM-02 in breast cancer, sponsored by Shanghai General Hospital. Primary endpoints: Visual Assessment of HER2 expression in Breast cancer using 99mTc-NM-02 SPECT/CT Scan at 1 year, Semiquantitative Assessment of Breast and other Metastatic Lesions in 99mTc-NM-02 SPECT/CT Scan at 1 year and 2 more. Started Jul 2019; status: completed.
02
Drugs
99mTc-NM-02
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04040686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040686.